News Sentiment

TVTX sentiment intelligence

Travere Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 56.59 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-0.6% over one week, +8.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -0.6% Price digesting
Trend fit Trend active 8.7% over four weeks
Fair value 192.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 43
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 10
Stock Titan 9
simplywall.st 4
Simply Wall Street 3
Investing.com 3
MT Newswires 3
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 13
Analyst action 5
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
BioSpace Direct company coverage

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2026

Travere Therapeutics announced inducement equity grants to six new employees on July 10, 2026, totaling 41,600 shares of common stock. These grants, comprising stock options and restricted stock units (RSUs), were made outside the 2018 Equity Incentive Plan as inducements for new

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 23:47
Source
BioSpace
TradingView Direct company coverage

RTRX6388605 Bond Risk Profile

This page provides a risk profile for the RTRX6388605 bond issued by Travere Therapeutics, Inc. The bond has a 0.5% coupon rate and matures on May 15, 2032. It details general bond information, including credit risk assessment and the ability to access analyst ratings.

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 17:40
Source
TradingView
TradingView Direct company coverage

RTRX6388605 Bond Profile — Key Metrics

This article provides a bond profile for RTRX6388605, a bond issued by Travere Therapeutics, Inc. Key metrics include an issue date of May 11, 2026, maturity date of May 15, 2032, and a coupon rate of 0.50%. The bond has an outstanding amount of $525 million USD and a face value

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 13:11
Source
TradingView
lincolnjournal.com Direct company coverage

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) announced inducement equity grants totaling 41,600 shares to six new employees on July 10, 2026. These grants, comprising stock options and restricted stock units (RSUs), were made as inducements for employment in accordance with Nasdaq L

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:47
Source
lincolnjournal.com
TradingView Direct company coverage

Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor

Travere Therapeutics announced that Sandra Calvin will retire as Chief Accounting Officer (CAO) and Principal Accounting Officer. John Torell, the current Vice President, Controller, is expected to succeed her to ensure a smooth transition. Torell is anticipated to serve as CAO a

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:12
Source
TradingView
Stock Titan Direct company coverage

Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires

Travere Therapeutics (NASDAQ: TVTX) announced that its chief accounting officer (CAO) and principal accounting officer (PAO), Sandra Calvin, plans to retire in February 2027 after the company files its Annual Report on Form 10-K. John Torell, the current Vice President, Controlle

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:10
Source
Stock Titan
Macau Business Direct company coverage

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines announced the closing of its exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a potential best-in-class oral BTK inhibitor. Under the agreement, Everest will receive an upfront payment of $112.5 million and is eligibl

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 09:09
Source
Macau Business
Simply Wall Street Direct company coverage

Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative?

Travere Therapeutics (TVTX) was recently removed from several Russell value and small-cap indices in late June 2026. This action could lead to forced portfolio rebalancing by index-tracking funds and reshape the company's investment narrative and risk profile, despite its core gr

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 14:41
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Travere Therapeutics (TVTX) Could Be 3% Undervalued As Russell Value Exits Stir Questions

Travere Therapeutics (TVTX) has been removed from several Russell value indices, prompting questions about its valuation. Despite this, the company has shown strong share price performance, with a 79.73% return over 90 days and a 289.73% return over one year. Simply Wall St indic

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 13:11
Source
Simply Wall Street
The National Law Review Direct company coverage

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application related to methods of using FILSPARI® (sparsentan) in IgA nephropathy. This patent is expected to provide U.S. coverage until October 2037 and will b

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 16:09
Source
The National Law Review
Simply Wall Street Direct company coverage

Is Travere Therapeutics (TVTX) Rebalancing Its Risk Profile With New Capital Tools And R&D Leadership Changes?

Travere Therapeutics recently experienced removal from Russell value and small-cap indices, filed a significant shelf registration for common stock, and announced upcoming changes in its R&D leadership. These developments prompt questions about how institutional ownership, fundin

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:39
Source
Simply Wall Street
marketscreener.com Direct company coverage

Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark

Travere Therapeutics, Inc. (NasdaqGM: TVTX) has been removed from the Russell 2000 Value Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including favorable analyst assessments of its drug Filspari and executive changes. The company remai

Tone
Negative 34/100
Event
Analyst action
Published
29 Jun 2026 15:12
Source
marketscreener.com
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (TVTX)

This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) with an "Overweight Bias" due to strong sentiment across all time horizons. It highlights the absence of resistance levels above the current price, suggesting upside potential. The piece also details three AI-generate

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 10:12
Source
Stock Traders Daily
TradingView Direct company coverage

Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX

This article provides financial information for Travere Therapeutics, Inc. (NASDAQ: TVTX), specifically focusing on its forward price-to-earnings ratio. It appears to be a stub or a data point from a financial platform like TradingView, indicating the period, value, and change fo

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 18:12
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX

The article provides the enterprise value to revenue forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It lists "Period," "Value," "Change," and "Change %" as key metrics related to this financial ratio. The information is presented within a TradingView interface, indicating

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 09:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX

The article focuses on the enterprise value to EBITDA forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The content itself seems to be a title with navigation an

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 15:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Travere Therapeutics, Inc. – NASDAQ:TVTX

The article discusses the enterprise value to EBIT forward for Travere Therapeutics, Inc. (NASDAQ: TVTX), a company in the Pharmaceuticals: Major sector. It appears to list financial data or an analysis of this metric, accessible on the TradingView platform.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 15:09
Source
TradingView
TradingView Direct company coverage

Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX)

This article provides an overview of Travere Therapeutics, Inc. (NASDAQ: TVTX) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details the company's financial performance, such as earnings per share and revenue,

Tone
Positive 67/100
Event
Earnings
Published
26 Jun 2026 16:41
Source
TradingView
GuruFocus Direct company coverage

TVTX Maintained by Guggenheim -- Price Target Raised to $65

Guggenheim analyst Vamil Divan maintained a 'Buy' rating for Travere Therapeutics (TVTX) and raised the price target to $65.00, reflecting confidence in the company's pipeline and future performance. Despite the positive analyst outlook, GuruFocus indicates that TVTX is significa

Tone
Positive 65/100
Event
Analyst action
Published
25 Jun 2026 15:15
Source
GuruFocus
TradingView Direct company coverage

TVTX Forecast — Price Target — Prediction for 2027

This article provides an overview of Travere Therapeutics, Inc. (TVTX) stock, including its current price, analyst forecasts, and recent financial performance. Analysts predict a price range of $43.00 to $70.00 for TVTX, with a consensus price target of $57.71. The company has sh

Tone
Positive 70/100
Event
Analyst action
Published
25 Jun 2026 13:11
Source
TradingView
Investing.com Direct company coverage

Travere Therapeutics stock hits 52-week high at 56.9 USD

Travere Therapeutics (TVTX) stock reached a new 52-week high of $56.90, reflecting a 267% total return over the past year and a market capitalization of $5.26 billion. InvestingPro analysis suggests the stock is undervalued, and recent developments include positive Phase 3 study

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 15:19
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Travere Therapeutics Inc For: 22 June By Investing.com

This article from Investing.com announces the filing of Form 4 for Travere Therapeutics Inc. on June 22. It is a brief public notice about the regulatory filing, indicating an insider transaction or change in ownership, without providing details within the snippet. Viewers are in

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 21:48
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4

Travere Therapeutics' Chief Medical Officer, Jula Inrig, reported a bona fide gift of 468 shares of common stock to a donor-advised fund. This charitable transfer occurred on June 22, 2026, and was reported at $0.00 per share, indicating a non-market transaction. Following this g

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:10
Source
Stock Titan